Gene editing in 2022 — Inside an Alzheimer's drug flop — M&A options for CVS

Subscribe to Insider View in browser


Welcome to Insider Healthcare. We're healthcare editors Lydia Ramsey Pflanzer and Leah Rosenbaum. Today in healthcare news:

If you're new to this newsletter, sign up here. Comments, tips? Email me at or tweet @leah_rosenbaum. Let's get to it...

First off, a quick reminder that today is the last edition before the newsletter goes on hiatus.

While we won't be in your inboxes every weekday during the hiatus, we do still want to keep you informed with the latest healthcare news.

Be sure to follow the healthcare team on Twitter at @HealthInsider, or email us at and if you have a tip or thought about what's going on in the world of healthcare.

Insider will be in touch soon with some newsletter updates. For now:

A hand with surgical glove replacing a section of DNA with tweezers, surrounded by dollar signsWhy 2022 will be CRISPR's most important year, according to more than 20 gene-editing experts

Dive in>>

A technician looks at a computer screen showing a brain scan.How a new hope for treating Alzheimer's turned into one of the worst drug launches in history

Read more>>

CVS pharmacyCVS Health's next frontier is primary care. Here are 8 companies the $132 billion retail giant might buy or work with to get there faster.

Check it out>>

We'll leave you with a few more great stories from this past month: 

- Lydia & Leah


Was this email forwarded to you?
Download on the app store   Get it on google play
You received this email because you signed up to this
Insider newsletter using the
Email preferences Unsubscribe
1 Liberty Plaza, 8th Floor. New York, NY 10006


Posts les plus consultés de ce blog

Chris Ramsey can take the heat, but what would relegation for QPR mean for black managers in the Premier League?

The Five Best Apps To Help You Lose Weight This Summer